Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
30.78
-0.81 (-2.56%)
At close: Dec 31, 2025, 4:00 PM EST
30.30
-0.48 (-1.54%)
After-hours: Dec 31, 2025, 7:47 PM EST

Lyell Immunopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
6531874898651,861-
Upgrade
Market Cap Growth
231.76%-61.73%-43.52%-53.52%--
Upgrade
Enterprise Value
378-215-45182992-
Upgrade
Last Close Price
30.7812.8038.8069.40154.80-
Upgrade
PS Ratio
15929.193065.303758.6610.22174.77-
Upgrade
PB Ratio
1.800.490.751.042.00-
Upgrade
P/TBV Ratio
1.980.490.751.042.00-
Upgrade
EV/Sales Ratio
9213.60--2.1593.15-
Upgrade
Debt / Equity Ratio
0.140.150.100.080.070.08
Upgrade
Asset Turnover
0000.080.010.01
Upgrade
Quick Ratio
10.036.8915.8217.2913.1512.43
Upgrade
Current Ratio
10.307.0616.0717.5913.4012.53
Upgrade
Return on Equity (ROE)
-75.75%-66.10%-31.53%-20.77%-30.36%-36.30%
Upgrade
Return on Assets (ROA)
-24.16%-22.05%-18.18%-11.32%-13.11%-18.76%
Upgrade
Return on Capital (ROIC)
-25.78%-23.59%-18.95%-12.31%-15.08%-22.73%
Upgrade
Return on Capital Employed (ROCE)
-52.80%-50.10%-34.30%-20.80%-19.80%-25.60%
Upgrade
Earnings Yield
-49.86%-183.44%-48.02%-21.17%-13.44%-
Upgrade
FCF Yield
-25.35%-87.10%-34.05%-22.40%-10.30%-
Upgrade
Buyback Yield / Dilution
-21.43%-4.18%-1.58%-81.79%-925.18%-144.21%
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q